Myasthenia Gravis
Conditions
Brief summary
This study called Multicenter Retrospective Study on the Short- and Medium-Term Efficacy and Tolerance of Zilucoplan Therapy in a Cohort of French Patients with Anti-AChR Myasthenia Gravis, is investigating the effects of a new treatment called Zilucoplan (generic name: ZILBRYSQ) on patients in France with a condition known as myasthenia gravis. Myasthenia gravis is an autoimmune disease that causes muscle weakness that worsens throughout the day with activity and impacts the ability to work and perform daily activities. The study aims to see if Zilucoplan can improve muscle strength and quality of life over three months, while also assessing its tolerance and safety by monitoring side effects. Researchers hope this treatment will offer significant benefits for people with this challenging condition.
Interventions
DRUGZilbrysq
Zilbrysq is a medicine used to treat generalized myasthenia gravis anti-AChR (a disease that leads to muscle weakness and tiredness) in adults whose immune system produces antibodies against a protein called the acetylcholine receptor. It is given as a subcutaneous injection (under the skin) once daily in a prefilled syringe that can be self-injected, and the dose depends on the patient's body weight. There are 3 available doses: 16.6 mg/0.416 mL for patients weighing less than 56 kg (123 lbs); 23 mg/0.574 mL for patients between 56 kg and less than 77 kg (123-170 lbs); and 32.4 mg/0.81 mL for patients weighing 77 kg and above (\>170 lbs). This can be injected into the abdomen, front of the thighs, and back of the upper arms (only if administered by a caregiver),
Sponsors
Centre Hospitalier Universitaire de Nice
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- Confirmed diagnosis of myasthenia gravis with anti-AChR antibodies in patients treated with Zilucoplan
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MG-ADL scores | At the inclusion, at 1 month, at 3 months and at 6 months | The MG-ADL is an 8-item patient-reported scale that measures myasthenia gravis symptoms and functional status. It assesses the impact of Myasthenia Gravis on the daily functions of the patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Garches scale scores | At the inclusion, at 1 month, at 3 months and at 6 months | The Garches scale is a 9-item based on clinical examination which measures the severity of myasthenia symptoms and muscle function. |
| Evaluation of tolerance (M6) through the description of type of Adverse events | At 6 months | Collect data on adverse events: total number of events, classification by type (mild, moderate, severe based on the Common Terminology Criteria for Adverse Events (CTCAE) scale) |
| Evaluation of tolerance (M6) through the description of the frequency of Adverse event | At 6 months | number of adverse event per month |
| Adverse events possible association with the treatment (causality) | At 6 months | causality (Certain / probable / possible / Unlikely / conditional / Unassessable) |
| Quality of life evaluation (MG-QoL15r) | At the inclusion, at 1 month, at 3 months and at 6 months | Myasthenia gravis quality of life-15 revised (MG-QoL51r) is a 15-item quality of life scale designed to assess important aspects of the patient's experience related to myasthenia gravis |
Countries
France
Contacts
Primary ContactSabrina Sacconi
Backup ContactAbderhmane Slioui
Outcome results
None listed